The Production of Complement Inhibitor Proteins in Mammalian Cell Lines—Light at the End of the Tunnel?
Open Access
- 14 March 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (3) , 646
Abstract
Therapeutic recombinant proteins are powerful tools used for the treatment of many detrimental diseases such as diabetes, cancer, multiple sclerosis, rheumatoid arthritis, hepatitis, and many more. Their importance in disease therapy is growing over small molecule drugs because of their advantages like specificity and reduced side effects. However, the large-scale production of certain recombinant proteins is still challenging despite impressive advancements in biomanufacturing. The complement cascade is considered a rich source of drug targets and natural regulator proteins with great therapeutic potential. However, the versatility of such proteins has been hampered by low production rates. The recent discoveries highlighted here may bring definite improvement in the large-scale recombinant production of complement inhibitor proteins or other difficult-to-express proteins in mammalian cell lines.Keywords
Funding Information
- National Research, Development and Innovation Office (GINOP-2.1.2-8-1-4-16-2017-0319, GINOP-1.2.15-21-2021-00006, 2020-1.1.6-JÖVŐ-2021-00010)
This publication has 105 references indexed in Scilit:
- Complement‐targeted therapeutics: An emerging field enabled by academic drug discoveryAmerican Journal of Hematology, 2023
- Complement activation during cardiopulmonary bypass and association with clinical outcomeseJHaem, 2022
- Expression vector cassette engineering for recombinant therapeutic production in mammalian cell systemsApplied Microbiology and Biotechnology, 2020
- Unraveling what makes a monoclonal antibody difficult‐to‐express: From intracellular accumulation to incomplete folding and degradation via ERADBiotechnology and Bioengineering, 2019
- Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry diseaseJournal of Inherited Metabolic Disease, 2019
- Intracellular response to process optimization and impact on productivity and product aggregates for a high‐titer CHO cell processBiotechnology and Bioengineering, 2017
- De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndromeHuman Mutation, 2006
- Bulk Production and Functional Analyses of Mouse CD55's Native and Deglycosylated Active DomainsArchives of Biochemistry and Biophysics, 2001
- Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the ratArthritis & Rheumatism, 2000
- Overexpression inEscherichia coli,Folding, Purification, and Characterization of the First Three Short Consensus Repeat Modules of Human Complement Receptor Type 1Protein Expression and Purification, 1995